South & Central America Anti-Obesity Drugs Market Size and Forecast (2021 - 2031)
The South & Central America Anti-Obesity Drugs Market is projected to grow significantly, reaching approximately US$ 1,094.6 million by 2031, up from US$ 248.9 million in 2024, with an estimated compound annual growth rate (CAGR) of 25.4% from 2025 to 2031.
Executive Summary and Market Analysis
The anti-obesity drugs market in South & Central America is divided into key regions: Brazil, Argentina, and the Rest of South & Central America. The market is expanding due to increasing obesity rates, heightened health awareness, and improved access to healthcare services. Factors such as sedentary lifestyles and changing dietary habits have led to a rise in obesity, prompting governments and health organizations to focus on weight management initiatives. Urbanization and economic growth have enhanced healthcare infrastructure and the availability of pharmaceutical products. Public health campaigns and media efforts have also contributed to reducing the stigma associated with obesity, encouraging more individuals to seek medical treatment. The introduction of innovative anti-obesity drugs, particularly GLP-1 receptor agonists, has further increased interest among patients and confidence among healthcare providers. Additionally, the rise of medical tourism in certain countries is making the region a destination for affordable treatments. These elements are collectively driving market growth and attracting investments from major pharmaceutical companies eager to meet the rising demand.
Strategic Insights
Market Segmentation Analysis
Emerging economies present significant opportunities for the anti-obesity drugs market, driven by rising obesity rates linked to urbanization and lifestyle changes. The enhancement of healthcare infrastructure and increased awareness of obesity-related health risks are fueling demand for effective treatments. Pharmaceutical companies are investing in these markets to address the unmet need for weight management solutions. Brazil, for instance, is improving its healthcare infrastructure and obesity management programs, creating a favorable environment for new anti-obesity medications. In April 2024, Brazil inaugurated a laboratory in Hortol?ndia, S?o Paulo, dedicated to producing diabetes and obesity medications, including liraglutide and semaglutide, with an investment of R$60 million (~US$ 10.93 million).
While initial access to anti-obesity medications may be limited to private markets and out-of-pocket payments, future insurance coverage and the introduction of generic versions in middle-income countries are expected to enhance accessibility. The increasing prevalence of obesity in emerging economies, combined with expanding healthcare infrastructure and growing awareness, is driving demand for anti-obesity drugs. Government initiatives and pharmaceutical investments are fostering a conducive environment for market growth, positioning emerging markets as key areas for expansion in the South & Central America anti-obesity drugs market.
Country Insights
The South & Central America Anti-Obesity Drugs Market is segmented by country into Brazil, Argentina, and the Rest of South & Central America, with the Rest of South & Central America holding the largest share in 2024. Notably, Chile, Colombia, Peru, and Bolivia are significant players in this market. Chile has the highest obesity rate in South America, with approximately 42% of adults classified as obese, projected to affect 14 million Chileans in the next five years. The rise in obesity is largely attributed to the availability of ultra-processed foods and sedentary lifestyles, leading to increased health issues such as type 2 diabetes and cardiovascular diseases.
Colombia has made significant healthcare reforms since the 1990s, resulting in approximately 97% of the population being covered under the social and health security system by 2023, facilitating greater access to obesity treatments and contributing to market growth.
Company Profiles
Key players in the South & Central America Anti-Obesity Drugs Market include GSK Plc, F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Ltd, Novo Nordisk AS, Eli Lilly and Co, Sun Pharmaceutical Industries Ltd, VIVUS LLC, Currax Pharmaceuticals LLC, AdvaCare Pharma USA LLC, and Rhythm Pharmaceuticals Inc. These companies are employing strategies such as expansion, product innovation, and mergers and acquisitions to enhance their market presence and offer innovative products.
Executive Summary and Market Analysis
The anti-obesity drugs market in South & Central America is divided into key regions: Brazil, Argentina, and the Rest of South & Central America. The market is expanding due to increasing obesity rates, heightened health awareness, and improved access to healthcare services. Factors such as sedentary lifestyles and changing dietary habits have led to a rise in obesity, prompting governments and health organizations to focus on weight management initiatives. Urbanization and economic growth have enhanced healthcare infrastructure and the availability of pharmaceutical products. Public health campaigns and media efforts have also contributed to reducing the stigma associated with obesity, encouraging more individuals to seek medical treatment. The introduction of innovative anti-obesity drugs, particularly GLP-1 receptor agonists, has further increased interest among patients and confidence among healthcare providers. Additionally, the rise of medical tourism in certain countries is making the region a destination for affordable treatments. These elements are collectively driving market growth and attracting investments from major pharmaceutical companies eager to meet the rising demand.
Strategic Insights
Market Segmentation Analysis
- By Type: The market is categorized into Prescription Drugs and OTC Drugs, with Prescription Drugs holding the largest market share in 2024.
- By Mechanism of Action: Segmented into Centrally Acting Drugs, Peripherally Acting Drugs, and Others, with Centrally Acting Drugs leading in market share in 2024.
- By Drug Class: Includes GLP-1 Agonists, Lipase Inhibitors, MC4R Agonists, and Others, where GLP-1 Agonists dominated the market in 2024.
- By GLP-1 Agonist: Further divided into Semaglutide, Liraglutide, and Tirzepatide (Zepbound), with Semaglutide having the largest share in 2024.
- By Application: Categories include Appetite Suppression, Inhibition of Fat Absorption, Metabolic Enhancement, and Combination, with Appetite Suppression leading in 2024.
- By Route of Administration: The market is segmented into Oral and Parenteral, with Oral being the most prevalent in 2024.
- By Distribution Channel: Includes Hospital Pharmacies, Online Channels, and Retail Pharmacies, with Hospital Pharmacies holding the largest share in 2024.
Emerging economies present significant opportunities for the anti-obesity drugs market, driven by rising obesity rates linked to urbanization and lifestyle changes. The enhancement of healthcare infrastructure and increased awareness of obesity-related health risks are fueling demand for effective treatments. Pharmaceutical companies are investing in these markets to address the unmet need for weight management solutions. Brazil, for instance, is improving its healthcare infrastructure and obesity management programs, creating a favorable environment for new anti-obesity medications. In April 2024, Brazil inaugurated a laboratory in Hortol?ndia, S?o Paulo, dedicated to producing diabetes and obesity medications, including liraglutide and semaglutide, with an investment of R$60 million (~US$ 10.93 million).
While initial access to anti-obesity medications may be limited to private markets and out-of-pocket payments, future insurance coverage and the introduction of generic versions in middle-income countries are expected to enhance accessibility. The increasing prevalence of obesity in emerging economies, combined with expanding healthcare infrastructure and growing awareness, is driving demand for anti-obesity drugs. Government initiatives and pharmaceutical investments are fostering a conducive environment for market growth, positioning emerging markets as key areas for expansion in the South & Central America anti-obesity drugs market.
Country Insights
The South & Central America Anti-Obesity Drugs Market is segmented by country into Brazil, Argentina, and the Rest of South & Central America, with the Rest of South & Central America holding the largest share in 2024. Notably, Chile, Colombia, Peru, and Bolivia are significant players in this market. Chile has the highest obesity rate in South America, with approximately 42% of adults classified as obese, projected to affect 14 million Chileans in the next five years. The rise in obesity is largely attributed to the availability of ultra-processed foods and sedentary lifestyles, leading to increased health issues such as type 2 diabetes and cardiovascular diseases.
Colombia has made significant healthcare reforms since the 1990s, resulting in approximately 97% of the population being covered under the social and health security system by 2023, facilitating greater access to obesity treatments and contributing to market growth.
Company Profiles
Key players in the South & Central America Anti-Obesity Drugs Market include GSK Plc, F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Ltd, Novo Nordisk AS, Eli Lilly and Co, Sun Pharmaceutical Industries Ltd, VIVUS LLC, Currax Pharmaceuticals LLC, AdvaCare Pharma USA LLC, and Rhythm Pharmaceuticals Inc. These companies are employing strategies such as expansion, product innovation, and mergers and acquisitions to enhance their market presence and offer innovative products.
1. INTRODUCTION
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
2.2 Market Attractiveness
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. ANTI-OBESITY DRUGS MARKET LANDSCAPE
4.1 Market Overview
4.2 PEST Analysis
5. SOUTH & CENTRAL AMERICA ANTI-OBESITY DRUGS MARKET - KEY MARKET DYNAMICS
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints:
6. ANTI-OBESITY DRUGS MARKET - SOUTH & CENTRAL AMERICA MARKET ANALYSIS
6.1 South & Central America Anti-Obesity Drugs Market Revenue (US$ Million), 2024 - 2031
6.2 South & Central America Anti-Obesity Drugs Market Forecast and Analysis
7. SOUTH & CENTRAL AMERICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY TYPE
7.1 Prescription Drugs
7.1.1 Overview
7.1.2 Prescription Drugs: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.2 OTC Drugs
7.2.1 Overview
7.2.2 OTC Drugs: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8. SOUTH & CENTRAL AMERICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY MECHANISM OF ACTION
8.1 Centrally Acting Drugs
8.1.1 Overview
8.1.2 Centrally Acting Drugs: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.2 Peripherally Acting Drugs
8.2.1 Overview
8.2.2 Peripherally Acting Drugs: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.3 Others
8.3.1 Overview
8.3.2 Others: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9. SOUTH & CENTRAL AMERICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY DRUG CLASS
9.1 GLP-1 Agonist
9.1.1 Overview
9.1.2 GLP-1 Agonist: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.2 Lipase Inhibitors
9.2.1 Overview
9.2.2 Lipase Inhibitors: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.3 MC4R agonist
9.3.1 Overview
9.3.2 MC4R agonist: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.4 Others
9.4.1 Overview
9.4.2 Others: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10. SOUTH & CENTRAL AMERICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY GLP-1 AGONIST
10.1 Semaglutide
10.1.1 Overview
10.1.2 Semaglutide: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.2 Liraglutide
10.2.1 Overview
10.2.2 Liraglutide: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.3 Tirzepatide (Zepbound)
10.3.1 Overview
10.3.2 Tirzepatide (Zepbound): South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11. SOUTH & CENTRAL AMERICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY APPLICATION
11.1 Appetite Suppression
11.1.1 Overview
11.1.2 Appetite Suppression: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.2 Inhibition of Fat Absorption or Digestive Enzymes
11.2.1 Overview
11.2.2 Inhibition of Fat Absorption or Digestive Enzymes: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.3 Metabolic Enhancement
11.3.1 Overview
11.3.2 Metabolic Enhancement: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.4 Combination
11.4.1 Overview
11.4.2 Combination: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
12. SOUTH & CENTRAL AMERICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY ROUTE OF ADMINISTRATION
12.1 Oral
12.1.1 Overview
12.1.2 Oral: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
12.2 Parenteral
12.2.1 Overview
12.2.2 Parenteral: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
13. SOUTH & CENTRAL AMERICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY DISTRIBUTION CHANNEL
13.1 Hospital Pharmacies
13.1.1 Overview
13.1.2 Hospital Pharmacies: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
13.2 Online Channel
13.2.1 Overview
13.2.2 Online Channel: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
13.3 Retail Pharmacies
13.3.1 Overview
13.3.2 Retail Pharmacies: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14. SOUTH & CENTRAL AMERICA ANTI-OBESITY DRUGS MARKET - COUNTRY ANALYSIS
14.1 South & Central America
14.1.1 South & Central America Anti-Obesity Drugs Market Revenue and Forecast and Analysis - by Country
14.1.1.1 South & Central America Anti-Obesity Drugs Market Revenue and Forecast and Analysis - by Country
14.1.2.2 Brazil: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14.1.2.2.1 Brazil: South & Central America Anti-Obesity Drugs Market Share - by Type
14.1.2.2.2 Brazil: South & Central America Anti-Obesity Drugs Market Share - by Mechanism Of Action
14.1.2.2.3 Brazil: South & Central America Anti-Obesity Drugs Market Share - by Drug Class
14.1.2.2.4 Brazil: South & Central America Anti-Obesity Drugs Market Share - by GLP-1 Agonist
14.1.2.2.5 Brazil: South & Central America Anti-Obesity Drugs Market Share - by Application
14.1.2.2.6 Brazil: South & Central America Anti-Obesity Drugs Market Share - by Route Of Administration
14.1.2.2.7 Brazil: South & Central America Anti-Obesity Drugs Market Share - by Distribution Channel
14.2.3.3 Argentina: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14.2.3.3.1 Argentina: South & Central America Anti-Obesity Drugs Market Share - by Type
14.2.3.3.2 Argentina: South & Central America Anti-Obesity Drugs Market Share - by Mechanism Of Action
14.2.3.3.3 Argentina: South & Central America Anti-Obesity Drugs Market Share - by Drug Class
14.2.3.3.4 Argentina: South & Central America Anti-Obesity Drugs Market Share - by GLP-1 Agonist
14.2.3.3.5 Argentina: South & Central America Anti-Obesity Drugs Market Share - by Application
14.2.3.3.6 Argentina: South & Central America Anti-Obesity Drugs Market Share - by Route Of Administration
14.2.3.3.7 Argentina: South & Central America Anti-Obesity Drugs Market Share - by Distribution Channel
14.3.4.4 Rest of South & Central America: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14.3.4.4.1 Rest of South & Central America: South & Central America Anti-Obesity Drugs Market Share - by Type
14.3.4.4.2 Rest of South & Central America: South & Central America Anti-Obesity Drugs Market Share - by Mechanism Of Action
14.3.4.4.3 Rest of South & Central America: South & Central America Anti-Obesity Drugs Market Share - by Drug Class
14.3.4.4.4 Rest of South & Central America: South & Central America Anti-Obesity Drugs Market Share - by GLP-1 Agonist
14.3.4.4.5 Rest of South & Central America: South & Central America Anti-Obesity Drugs Market Share - by Application
14.3.4.4.6 Rest of South & Central America: South & Central America Anti-Obesity Drugs Market Share - by Route Of Administration
14.3.4.4.7 Rest of South & Central America: South & Central America Anti-Obesity Drugs Market Share - by Distribution Channel
15 COMPETITIVE LANDSCAPE
15.1 Heat Map Analysis by Key Players
15.2 Company Positioning & Concentration
16 INDUSTRY LANDSCAPE
16.1 Overview
16.2 New Product Development
16.3 Merger and Acquisition
16.4 Other Strategic Developments
17 COMPANY PROFILES
17.1 GSK Plc
17.1.1 Key Facts
17.1.2 Business Description
17.1.3 Products and Services
17.1.4 Financial Overview
17.1.5 SWOT Analysis
17.1.6 Key Developments
17.2 F. Hoffmann-La Roche Ltd
17.2.1 Key Facts
17.2.2 Business Description
17.2.3 Products and Services
17.2.4 Financial Overview
17.2.5 SWOT Analysis
17.2.6 Key Developments
17.3 Teva Pharmaceutical Industries Ltd
17.3.1 Key Facts
17.3.2 Business Description
17.3.3 Products and Services
17.3.4 Financial Overview
17.3.5 SWOT Analysis
17.3.6 Key Developments
17.4 Novo Nordisk AS
17.4.1 Key Facts
17.4.2 Business Description
17.4.3 Products and Services
17.4.4 Financial Overview
17.4.5 SWOT Analysis
17.4.6 Key Developments
17.5 Eli Lilly and Co
17.5.1 Key Facts
17.5.2 Business Description
17.5.3 Products and Services
17.5.4 Financial Overview
17.5.5 SWOT Analysis
17.5.6 Key Developments
17.6 Sun Pharmaceutical Industries Ltd
17.6.1 Key Facts
17.6.2 Business Description
17.6.3 Products and Services
17.6.4 Financial Overview
17.6.5 SWOT Analysis
17.6.6 Key Developments
17.7 VIVUS LLC
17.7.1 Key Facts
17.7.2 Business Description
17.7.3 Products and Services
17.7.4 Financial Overview
17.7.5 SWOT Analysis
17.7.6 Key Developments
17.8 Currax Pharmaceuticals LLC.
17.8.1 Key Facts
17.8.2 Business Description
17.8.3 Products and Services
17.8.4 Financial Overview
17.8.5 SWOT Analysis
17.8.6 Key Developments
17.9 AdvaCare Pharma USA LLC
17.9.1 Key Facts
17.9.2 Business Description
17.9.3 Products and Services
17.9.4 Financial Overview
17.9.5 SWOT Analysis
17.9.6 Key Developments
17.10 Rhythm Pharmaceuticals Inc
17.10.1 Key Facts
17.10.2 Business Description
17.10.3 Products and Services
17.10.4 Financial Overview
17.10.5 SWOT Analysis
17.10.6 Key Developments
18. APPENDIX
18.1 About The Insight Partners
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
2.2 Market Attractiveness
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. ANTI-OBESITY DRUGS MARKET LANDSCAPE
4.1 Market Overview
4.2 PEST Analysis
5. SOUTH & CENTRAL AMERICA ANTI-OBESITY DRUGS MARKET - KEY MARKET DYNAMICS
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints:
6. ANTI-OBESITY DRUGS MARKET - SOUTH & CENTRAL AMERICA MARKET ANALYSIS
6.1 South & Central America Anti-Obesity Drugs Market Revenue (US$ Million), 2024 - 2031
6.2 South & Central America Anti-Obesity Drugs Market Forecast and Analysis
7. SOUTH & CENTRAL AMERICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY TYPE
7.1 Prescription Drugs
7.1.1 Overview
7.1.2 Prescription Drugs: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.2 OTC Drugs
7.2.1 Overview
7.2.2 OTC Drugs: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8. SOUTH & CENTRAL AMERICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY MECHANISM OF ACTION
8.1 Centrally Acting Drugs
8.1.1 Overview
8.1.2 Centrally Acting Drugs: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.2 Peripherally Acting Drugs
8.2.1 Overview
8.2.2 Peripherally Acting Drugs: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.3 Others
8.3.1 Overview
8.3.2 Others: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9. SOUTH & CENTRAL AMERICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY DRUG CLASS
9.1 GLP-1 Agonist
9.1.1 Overview
9.1.2 GLP-1 Agonist: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.2 Lipase Inhibitors
9.2.1 Overview
9.2.2 Lipase Inhibitors: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.3 MC4R agonist
9.3.1 Overview
9.3.2 MC4R agonist: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.4 Others
9.4.1 Overview
9.4.2 Others: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10. SOUTH & CENTRAL AMERICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY GLP-1 AGONIST
10.1 Semaglutide
10.1.1 Overview
10.1.2 Semaglutide: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.2 Liraglutide
10.2.1 Overview
10.2.2 Liraglutide: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.3 Tirzepatide (Zepbound)
10.3.1 Overview
10.3.2 Tirzepatide (Zepbound): South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11. SOUTH & CENTRAL AMERICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY APPLICATION
11.1 Appetite Suppression
11.1.1 Overview
11.1.2 Appetite Suppression: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.2 Inhibition of Fat Absorption or Digestive Enzymes
11.2.1 Overview
11.2.2 Inhibition of Fat Absorption or Digestive Enzymes: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.3 Metabolic Enhancement
11.3.1 Overview
11.3.2 Metabolic Enhancement: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
11.4 Combination
11.4.1 Overview
11.4.2 Combination: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
12. SOUTH & CENTRAL AMERICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY ROUTE OF ADMINISTRATION
12.1 Oral
12.1.1 Overview
12.1.2 Oral: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
12.2 Parenteral
12.2.1 Overview
12.2.2 Parenteral: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
13. SOUTH & CENTRAL AMERICA ANTI-OBESITY DRUGS MARKET REVENUE ANALYSIS - BY DISTRIBUTION CHANNEL
13.1 Hospital Pharmacies
13.1.1 Overview
13.1.2 Hospital Pharmacies: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
13.2 Online Channel
13.2.1 Overview
13.2.2 Online Channel: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
13.3 Retail Pharmacies
13.3.1 Overview
13.3.2 Retail Pharmacies: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14. SOUTH & CENTRAL AMERICA ANTI-OBESITY DRUGS MARKET - COUNTRY ANALYSIS
14.1 South & Central America
14.1.1 South & Central America Anti-Obesity Drugs Market Revenue and Forecast and Analysis - by Country
14.1.1.1 South & Central America Anti-Obesity Drugs Market Revenue and Forecast and Analysis - by Country
14.1.2.2 Brazil: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14.1.2.2.1 Brazil: South & Central America Anti-Obesity Drugs Market Share - by Type
14.1.2.2.2 Brazil: South & Central America Anti-Obesity Drugs Market Share - by Mechanism Of Action
14.1.2.2.3 Brazil: South & Central America Anti-Obesity Drugs Market Share - by Drug Class
14.1.2.2.4 Brazil: South & Central America Anti-Obesity Drugs Market Share - by GLP-1 Agonist
14.1.2.2.5 Brazil: South & Central America Anti-Obesity Drugs Market Share - by Application
14.1.2.2.6 Brazil: South & Central America Anti-Obesity Drugs Market Share - by Route Of Administration
14.1.2.2.7 Brazil: South & Central America Anti-Obesity Drugs Market Share - by Distribution Channel
14.2.3.3 Argentina: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14.2.3.3.1 Argentina: South & Central America Anti-Obesity Drugs Market Share - by Type
14.2.3.3.2 Argentina: South & Central America Anti-Obesity Drugs Market Share - by Mechanism Of Action
14.2.3.3.3 Argentina: South & Central America Anti-Obesity Drugs Market Share - by Drug Class
14.2.3.3.4 Argentina: South & Central America Anti-Obesity Drugs Market Share - by GLP-1 Agonist
14.2.3.3.5 Argentina: South & Central America Anti-Obesity Drugs Market Share - by Application
14.2.3.3.6 Argentina: South & Central America Anti-Obesity Drugs Market Share - by Route Of Administration
14.2.3.3.7 Argentina: South & Central America Anti-Obesity Drugs Market Share - by Distribution Channel
14.3.4.4 Rest of South & Central America: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
14.3.4.4.1 Rest of South & Central America: South & Central America Anti-Obesity Drugs Market Share - by Type
14.3.4.4.2 Rest of South & Central America: South & Central America Anti-Obesity Drugs Market Share - by Mechanism Of Action
14.3.4.4.3 Rest of South & Central America: South & Central America Anti-Obesity Drugs Market Share - by Drug Class
14.3.4.4.4 Rest of South & Central America: South & Central America Anti-Obesity Drugs Market Share - by GLP-1 Agonist
14.3.4.4.5 Rest of South & Central America: South & Central America Anti-Obesity Drugs Market Share - by Application
14.3.4.4.6 Rest of South & Central America: South & Central America Anti-Obesity Drugs Market Share - by Route Of Administration
14.3.4.4.7 Rest of South & Central America: South & Central America Anti-Obesity Drugs Market Share - by Distribution Channel
15 COMPETITIVE LANDSCAPE
15.1 Heat Map Analysis by Key Players
15.2 Company Positioning & Concentration
16 INDUSTRY LANDSCAPE
16.1 Overview
16.2 New Product Development
16.3 Merger and Acquisition
16.4 Other Strategic Developments
17 COMPANY PROFILES
17.1 GSK Plc
17.1.1 Key Facts
17.1.2 Business Description
17.1.3 Products and Services
17.1.4 Financial Overview
17.1.5 SWOT Analysis
17.1.6 Key Developments
17.2 F. Hoffmann-La Roche Ltd
17.2.1 Key Facts
17.2.2 Business Description
17.2.3 Products and Services
17.2.4 Financial Overview
17.2.5 SWOT Analysis
17.2.6 Key Developments
17.3 Teva Pharmaceutical Industries Ltd
17.3.1 Key Facts
17.3.2 Business Description
17.3.3 Products and Services
17.3.4 Financial Overview
17.3.5 SWOT Analysis
17.3.6 Key Developments
17.4 Novo Nordisk AS
17.4.1 Key Facts
17.4.2 Business Description
17.4.3 Products and Services
17.4.4 Financial Overview
17.4.5 SWOT Analysis
17.4.6 Key Developments
17.5 Eli Lilly and Co
17.5.1 Key Facts
17.5.2 Business Description
17.5.3 Products and Services
17.5.4 Financial Overview
17.5.5 SWOT Analysis
17.5.6 Key Developments
17.6 Sun Pharmaceutical Industries Ltd
17.6.1 Key Facts
17.6.2 Business Description
17.6.3 Products and Services
17.6.4 Financial Overview
17.6.5 SWOT Analysis
17.6.6 Key Developments
17.7 VIVUS LLC
17.7.1 Key Facts
17.7.2 Business Description
17.7.3 Products and Services
17.7.4 Financial Overview
17.7.5 SWOT Analysis
17.7.6 Key Developments
17.8 Currax Pharmaceuticals LLC.
17.8.1 Key Facts
17.8.2 Business Description
17.8.3 Products and Services
17.8.4 Financial Overview
17.8.5 SWOT Analysis
17.8.6 Key Developments
17.9 AdvaCare Pharma USA LLC
17.9.1 Key Facts
17.9.2 Business Description
17.9.3 Products and Services
17.9.4 Financial Overview
17.9.5 SWOT Analysis
17.9.6 Key Developments
17.10 Rhythm Pharmaceuticals Inc
17.10.1 Key Facts
17.10.2 Business Description
17.10.3 Products and Services
17.10.4 Financial Overview
17.10.5 SWOT Analysis
17.10.6 Key Developments
18. APPENDIX
18.1 About The Insight Partners
LIST OF TABLES
Table 1. South & Central America Anti-Obesity Drugs Market Segmentation
Table 2. List of Vendors
Table 3. South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Table 4. South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 5. South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 6. South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 7. South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Glp-1 Agonist
Table 8. South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 9. South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 10. South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 11. South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Country
Table 12. Brazil: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 13. Brazil: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 14. Brazil: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 15. Brazil: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Glp-1 Agonist
Table 16. Brazil: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 17. Brazil: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 18. Brazil: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 19. Argentina: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 20. Argentina: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 21. Argentina: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 22. Argentina: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Glp-1 Agonist
Table 23. Argentina: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 24. Argentina: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 25. Argentina: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 26. Rest of South & Central America: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 27. Rest of South & Central America: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 28. Rest of South & Central America: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 29. Rest of South & Central America: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Glp-1 Agonist
Table 30. Rest of South & Central America: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 31. Rest of South & Central America: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 32. Rest of South & Central America: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 33. Heat Map Analysis by Key Players
Table 1. South & Central America Anti-Obesity Drugs Market Segmentation
Table 2. List of Vendors
Table 3. South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Table 4. South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 5. South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 6. South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 7. South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Glp-1 Agonist
Table 8. South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 9. South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 10. South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 11. South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Country
Table 12. Brazil: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 13. Brazil: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 14. Brazil: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 15. Brazil: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Glp-1 Agonist
Table 16. Brazil: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 17. Brazil: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 18. Brazil: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 19. Argentina: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 20. Argentina: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 21. Argentina: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 22. Argentina: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Glp-1 Agonist
Table 23. Argentina: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 24. Argentina: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 25. Argentina: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 26. Rest of South & Central America: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Type
Table 27. Rest of South & Central America: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Mechanism Of Action
Table 28. Rest of South & Central America: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Drug Class
Table 29. Rest of South & Central America: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Glp-1 Agonist
Table 30. Rest of South & Central America: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Application
Table 31. Rest of South & Central America: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Route Of Administration
Table 32. Rest of South & Central America: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Distribution Channel
Table 33. Heat Map Analysis by Key Players
LIST OF FIGURES
Figure 1. South & Central America Anti-Obesity Drugs Market Segmentation - Country
Figure 2. PEST Analysis
Figure 4. South & Central America Anti-Obesity Drugs Market - Key Market Dynamics
Figure 5. Impact Analysis of Drivers and Restraints
Figure 6. South & Central America Anti-Obesity Drugs Market Revenue (US$ Million), 2024 - 2031
Figure 7. South & Central America Anti-Obesity Drugs Market Share (%) - by Type, 2024 and 2031
Figure 8. Prescription Drugs: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 9. OTC Drugs: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 10. South & Central America Anti-Obesity Drugs Market Share (%) - by Mechanism Of Action, 2024 and 2031
Figure 11. Centrally Acting Drugs: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 12. Peripherally Acting Drugs: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 13. Others: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 14. South & Central America Anti-Obesity Drugs Market Share (%) - by Drug Class, 2024 and 2031
Figure 15. GLP-1 Agonist: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 16. Lipase Inhibitors: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 17. MC4R agonist: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 18. Others: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 19. South & Central America Anti-Obesity Drugs Market Share (%) - by GLP-1 Agonist, 2024 and 2031
Figure 20. Semaglutide: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 21. Liraglutide: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 22. Tirzepatide (Zepbound): South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 23. South & Central America Anti-Obesity Drugs Market Share (%) - by Application, 2024 and 2031
Figure 24. Appetite Suppression: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 25. Inhibition of Fat Absorption or Digestive Enzymes: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 26. Metabolic Enhancement: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 27. Combination: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 28. South & Central America Anti-Obesity Drugs Market Share (%) - by Route Of Administration, 2024 and 2031
Figure 29. Oral: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 30. Parenteral: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 31. South & Central America Anti-Obesity Drugs Market Share (%) - by Distribution Channel, 2024 and 2031
Figure 32. Hospital Pharmacies: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 33. Online Channel: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 34. Retail Pharmacies: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 35. South & Central America Anti-Obesity Drugs Market Breakdown by Key Countries, 2024 and 2031 (%)
Figure 36. Brazil: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 37. Argentina: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 38. Rest of South & Central America: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 39. Company Positioning & Concentration
Figure 1. South & Central America Anti-Obesity Drugs Market Segmentation - Country
Figure 2. PEST Analysis
Figure 4. South & Central America Anti-Obesity Drugs Market - Key Market Dynamics
Figure 5. Impact Analysis of Drivers and Restraints
Figure 6. South & Central America Anti-Obesity Drugs Market Revenue (US$ Million), 2024 - 2031
Figure 7. South & Central America Anti-Obesity Drugs Market Share (%) - by Type, 2024 and 2031
Figure 8. Prescription Drugs: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 9. OTC Drugs: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 10. South & Central America Anti-Obesity Drugs Market Share (%) - by Mechanism Of Action, 2024 and 2031
Figure 11. Centrally Acting Drugs: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 12. Peripherally Acting Drugs: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 13. Others: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 14. South & Central America Anti-Obesity Drugs Market Share (%) - by Drug Class, 2024 and 2031
Figure 15. GLP-1 Agonist: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 16. Lipase Inhibitors: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 17. MC4R agonist: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 18. Others: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 19. South & Central America Anti-Obesity Drugs Market Share (%) - by GLP-1 Agonist, 2024 and 2031
Figure 20. Semaglutide: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 21. Liraglutide: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 22. Tirzepatide (Zepbound): South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 23. South & Central America Anti-Obesity Drugs Market Share (%) - by Application, 2024 and 2031
Figure 24. Appetite Suppression: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 25. Inhibition of Fat Absorption or Digestive Enzymes: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 26. Metabolic Enhancement: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 27. Combination: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 28. South & Central America Anti-Obesity Drugs Market Share (%) - by Route Of Administration, 2024 and 2031
Figure 29. Oral: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 30. Parenteral: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 31. South & Central America Anti-Obesity Drugs Market Share (%) - by Distribution Channel, 2024 and 2031
Figure 32. Hospital Pharmacies: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 33. Online Channel: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 34. Retail Pharmacies: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 35. South & Central America Anti-Obesity Drugs Market Breakdown by Key Countries, 2024 and 2031 (%)
Figure 36. Brazil: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 37. Argentina: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 38. Rest of South & Central America: South & Central America Anti-Obesity Drugs Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 39. Company Positioning & Concentration
